Breaking News Instant updates and real-time market news.

ONCS

OncoSec

$0.81

-0.0557 (-6.40%)

08:34
12/10/18
12/10
08:34
12/10/18
08:34

OncoSec receives $7M investment from Alpha Holdings at $1.50 per share

OncoSec Medical announced that the company has received a $7M investment at $1.50 per share from Alpha Holdings as part of a fundamental strategic investment centered on the clinical development of OncoSec's lead immunotherapy product candidate, TAVO. Under the terms of the stock purchase agreement, Alpha Holdings purchased $7M worth of shares of common stock from OncoSec at $1.50 per share. The investment was executed on December 6 and completes a commitment to OncoSec by Alpha Holdings to purchase a total value of $15M shares of common stock priced at $1.50 per share.

ONCS OncoSec
$0.81

-0.0557 (-6.40%)

11/07/18
HCWC
11/07/18
DOWNGRADE
Target $1
HCWC
Neutral
OncoSec downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded OncoSec to Neutral from Buy after the company reported preliminary top-line data from the PISCES/KEYNOTE-695 trial of TAVO with Keytruda in metastatic melanoma patients who have failed anti-PD-1 therapy, stating that his first impression is that the early efficacy results are "underwhelming." He noted that other second generation I/O agents have demonstrated higher response rates and while TAVO may eventually obtain regulatory approval, its efficacy may not be differentiated enough for wide market adoption. Selvaraju lowered his price target on OncoSec shares to $1 from $4.
11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
10/15/18
PIPR
10/15/18
NO CHANGE
Target $5
PIPR
Overweight
Piper reiterates Overweight on OncoSec with $5 price target
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on OncoSec Medical with a $5 price target after the company announced it initiated a Phase II study of tavokinogene telseplasmid plus Keytruda in and triple negative breast cancer patients who have received one prior chemo or immunotherapy with preliminary data in 2019. The primary driver for OncoSec shares remains the Stage 1 Phase IIb Pisces data on tavokinogene telseplasmid plus Keytruda in PD-1 refractory melanoma in November, Tenthoff tells investors in a research note. He points out that depending on the data, OncoSec may initiate Stage 2 of the study, which could serve as the basis for accelerated approval in melanoma in 2020.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $5
PIPR
Overweight
OncoSec price target raised to $5 from $4 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for OncoSec Medical to $5 saying tavokinogene telseplasmid has demonstrated proof-of-concept data in relapsed/refractory melanoma. The analyst expects final Phase II OMS-100 monotherapy plus preliminary Phase IIb data at the Society for Immunotherapy of Cancer meeting in November. Depending upon the strength of data in Stage 2 of this trial, OncoSec may be able to seek accelerated approval in melanoma in 2020, Tenthoff tells investors in a research note after taking over coverage of the name. He maintains Piper's Overweight rating on OncoSec.

TODAY'S FREE FLY STORIES

BT

BT Group

$0.00

(0.00%)

04:53
11/18/19
11/18
04:53
11/18/19
04:53
Downgrade
BT Group rating change  »

BT Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

VSAT

ViaSat

$71.86

0.66 (0.93%)

04:50
11/18/19
11/18
04:50
11/18/19
04:50
Upgrade
ViaSat rating change  »

ViaSat upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BRP

BRP Group

$17.47

-0.03 (-0.17%)

04:49
11/18/19
11/18
04:49
11/18/19
04:49
Initiation
BRP Group initiated  »

BRP Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VBHLF

Virgin Australia Holdings

$0.00

(0.00%)

04:47
11/18/19
11/18
04:47
11/18/19
04:47
Upgrade
Virgin Australia Holdings rating change  »

Virgin Australia Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCLAY

Coca-Cola Amatil

$0.00

(0.00%)

04:46
11/18/19
11/18
04:46
11/18/19
04:46
Upgrade
Coca-Cola Amatil rating change  »

Coca-Cola Amatil upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCLAY

Coca-Cola Amatil

$0.00

(0.00%)

04:45
11/18/19
11/18
04:45
11/18/19
04:45
Upgrade
Coca-Cola Amatil rating change  »

Coca-Cola Amatil upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCLAY

Coca-Cola Amatil

$0.00

(0.00%)

04:45
11/18/19
11/18
04:45
11/18/19
04:45
Initiation
Coca-Cola Amatil initiated  »

Coca-Cola Amatil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$37.00

0.2 (0.54%)

04:44
11/18/19
11/18
04:44
11/18/19
04:44
Upgrade
HSBC rating change  »

HSBC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

, FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

04:42
11/18/19
11/18
04:42
11/18/19
04:42
Downgrade
Peugeot, Fiat Chrysler rating change  »

Peugeot downgraded to…

PUGOY

Peugeot

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

03:55
11/18/19
11/18
03:55
11/18/19
03:55
General news
FX Action: USD-CAD has nudged to a 10-day low »

FX Action: USD-CAD has…

03:15
11/18/19
11/18
03:15
11/18/19
03:15
General news
FX Update: Sterling has rallied on weekend polls »

FX Update: Sterling has…

01:50
11/18/19
11/18
01:50
11/18/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

HPQ

HP Inc.

$20.17

0.05 (0.25%)

, XRX

Xerox

$38.95

0.295 (0.76%)

20:56
11/17/19
11/17
20:56
11/17/19
20:56
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

HPQ

HP Inc.

$20.17

0.05 (0.25%)

XRX

Xerox

$38.95

0.295 (0.76%)

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

PCG

PG&E

$7.41

0.71 (10.60%)

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

SNE

Sony

$62.03

0.23 (0.37%)

BR

Broadridge

$119.80

0.485 (0.41%)

MDT

Medtronic

$112.11

2.9 (2.66%)

DIS

Disney

$144.63

-2.56 (-1.74%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 09

    Dec

  • 07

    Jan

RCEL

Avita Medical

$8.13

-0.06 (-0.73%)

20:39
11/17/19
11/17
20:39
11/17/19
20:39
Hot Stocks
Avita Medical appoints David McIntyre CFO »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

20:37
11/17/19
11/17
20:37
11/17/19
20:37
Recommendations
Eidos Therapeutics analyst commentary at Piper Jaffray »

Piper Jaffray sees Eidos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

COO

Cooper Companies

$301.97

2.64 (0.88%)

20:30
11/17/19
11/17
20:30
11/17/19
20:30
Recommendations
Cooper Companies analyst commentary at Piper Jaffray »

Piper Jaffray reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CRM

Salesforce

$163.20

0.18 (0.11%)

20:21
11/17/19
11/17
20:21
11/17/19
20:21
Recommendations
Salesforce analyst commentary at Jefferies »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 16

    Dec

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Breaking Earnings news story on Cabot Microelectronics »

Cabot Microelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Cabot Microelectronics sees Q1 total revenue approximately flat »

For Q1, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:14
11/17/19
11/17
20:14
11/17/19
20:14
Earnings
Cabot Microelectronics reports Q4 EPS $1.68, consensus $1.63 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

JEF

Jefferies Financial Group

$19.08

0.16 (0.85%)

20:13
11/17/19
11/17
20:13
11/17/19
20:13
Hot Stocks
Jefferies Financial Group to sell 31% interest in National Beef to Marfrig »

Jefferies Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NIO

NIO Inc.

$1.82

0.07 (4.01%)

20:11
11/17/19
11/17
20:11
11/17/19
20:11
Hot Stocks
NIO Inc. appoints Wei Feng CFO »

NIO Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

20:09
11/17/19
11/17
20:09
11/17/19
20:09
Hot Stocks
Barrick Gold to sell 50% stake in Australian mine for $750M in cash »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

15:40
11/17/19
11/17
15:40
11/17/19
15:40
Periodicals
Saracen close to buying Barrick Gold mine stake for $750M, Bloomberg says »

Saracen Mineral Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$40.51

0.67 (1.68%)

15:11
11/17/19
11/17
15:11
11/17/19
15:11
Hot Stocks
Esperion presents pooled analyses from four Phase 3 bempedoic acid studies »

Esperion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.